Search clinical trials for: ALXN1850

Total 77 results

Alexion Pharmaceuticals, Inc.

Not yet recruiting

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (MULBERRY)

Hypophosphatasia

United States, Taiwan, Thailand, Vietnam, United Kingdom, Korea, Republic of, Israel, Italy, Australia, Turkey, France, Poland, Germany, Spain, Belgium, China, Canada, Brazil, Argentina, Mexico
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Israel, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Poland, Turkey, Brazil, Thailand, United Kingdom, Canada, Slovakia, Czechia
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

United States, Japan, Germany, Turkey, Italy, India, Australia, France, United Kingdom, Argentina, Canada
Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Alexion Pharmaceuticals

Completed

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Wilson Disease

United States, Germany, Austria, Poland, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

Wilson Disease

United Kingdom
Alexion

Active, not recruiting

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease (PHOENIX)

Sickle Cell Disease (SCD)

United States, France
Alexion Pharmaceuticals, Inc.

Terminated

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals

Withdrawn

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
Alexion Pharmaceuticals

Terminated

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Warm Autoimmune Hemolytic Anemia

United States, Jordan
Alexion Pharmaceuticals

Terminated

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Pemphigus | Pemphigus Vulgaris | Pemphigus Foliaceus

United States
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Hypophosphatasia

United States
Alexion Pharmaceuticals
Syneos Health

Terminated

A Study of ALXN1830 in Healthy Adult Participants

Healthy

New Zealand
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Alexion Pharmaceuticals

Completed

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Healthy

United Kingdom
Alexion Pharmaceuticals

Withdrawn

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion Pharmaceuticals, Inc.

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

Healthy Participants

New Zealand
Alexion Pharmaceuticals

Completed

Copper Balance in Healthy Participants Administered ALXN1840

Healthy

United Kingdom
Alexion

Withdrawn

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion

Completed

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Wilson Disease

United States, New Zealand, United Kingdom
Alexion Pharmaceuticals, Inc.

Terminated

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Italy, Spain, Canada, Germany, Korea, Republic of, Serbia, Taiwan
Alexion

Completed

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Proteinuria

Korea, Republic of
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
Alexion Pharmaceuticals, Inc.
Parexel

Recruiting

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Healthy Adult Participants

Canada, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

China, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion Pharmaceuticals, Inc.

Terminated

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Wilson Disease

Spain, Korea, Republic of, France, Germany, Japan, Australia, Poland, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Military Institute od Medicine National Research...
ABM Industries

Recruiting

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. (COVMENT)

Nervous System Diseases

Poland
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Alexion Pharmaceuticals, Inc.

Completed

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

Healthy

United Kingdom
Alexion Pharmaceuticals

Completed

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

Korea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Italy, United States, Korea, Republic of, Spain, Germany, Belgium, United Kingdom
Alexion

Completed

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

France, United Kingdom, Norway, Russian Federation, Netherlands, United States
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Alexion

Active, not recruiting

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, United Kingdom
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Alexion Pharmaceuticals, Inc.

Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

Italy, Spain, Belgium, France, Turkey, Austria, Brazil, Netherlands, Australia, Finland, Russian Federation, Sweden, Canada, United States
Alexion Pharmaceuticals

Completed

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Alexion

Recruiting

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Neuromyelitis Optica Spectrum Disorder

France, United States, Japan, Spain, Canada, Korea, Republic of, Italy
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Dermatomyositis

Italy, Spain, United States, France, Germany, Korea, Republic of, United Kingdom, Poland, Japan

Search clinical trials for: ALXN1850

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations